Clara Rodríguez Fernández, Author at Labiotech.eu

About

Traveler, musician, food enthusiast and book worm. Always on the hunt for interesting facts and news.

Articles by Clara Rodríguez Fernández

News and Trends 9 Nov 2016

British Artificial Intelligence will soon run Clinical Trials

Artificial Intelligence can make clinical trials cheaper and faster, and this British start-up is about to start testing its technology to optimize drug development. BenevolentAI is a London start-up that specializes in artificial intelligence (AI); its BenevolentBio division, formerly Stratified Medical, applies AI to human health and biotech. Its baby is a technology that could speed […]

November 9, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 9 Nov 2016

Up, up and away! CureVac’s money pile now Totals €325M

CureVac has raised an additional €27M ($29.5M) that will help the company keep on its track to be the first one to launch a mRNA therapy, a technology that can revolutionize how drugs are designed. CureVac is a German company in the billion-euro biotech club at the forefront of messenger RNA (mRNA) therapies, a technology that […]

November 9, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 8 Nov 2016

These companies want to use Stem Cells to improve Drug Safety

Axiogenesis and Metrion Biosciences will use stem cells to improve preclinical neurotoxicity and cardiac safety testing, a feat that can significantly reduce the time and cost of drug discovery and clinical development. Axiogenesis is a Biotech from Cologne, Germany, that develops cell lines derived from induced pluripotent stem cells (iPSCs) for preclinical applications. The company […]

November 8, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 7 Nov 2016

Green Light for Genfit to Tackle another Liver Disease

The FDA has cleared Genfit’s IND application to treat a second liver disease with a big unmet clinical need. With this new step forward, the company gets even closer to become the leader in liver disease treatments. After a very successful fundraising last week, Genfit is kicking off the week with good news from the […]

November 7, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 7 Nov 2016

Results from 45% of Clinical Trials are kept Secret

A new transparency study has identified Sanofi, Novartis and GSK as the companies that keep the most clinical trial results unreported. TrialsTracker is a tool developed at the University of Oxford that automatically rates transparency on clinical trials by checking if there are results available in clinicaltrials.gov and PubMed. The results: globally, 45% of data on […]

November 7, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 11 02 at 6 e1478106664568

News and Trends 7 Nov 2016

The Mind Behind the Artificial Pancreas that Could Change the Lives of Diabetics

We had the opportunity to talk with Roman Hovorka, from The University of Cambridge, who’s working on a revolutionary medical device that can automatically improve glucose levels in people with type 1 diabetes. An artificial pancreas is a device that measures glucose levels and responds by injecting the right amount of insulin required at any […]

November 7, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 5 Nov 2016

Would you Taste this Gene-Edited Dinner?

Genetic engineering can make food healthier, improve nutrition and reduce environmental impact. To demonstrate its potential, Cellectis hosted a dinner featuring futuristic food technology. Cellectis is a French company that develops immuno-oncology therapies and became famous last year when its CAR-T treatment saved a 1-year old girl from leukemia. Its gene-editing TALEN technology is also used by […]

November 5, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 Nov 2016

This Company has developed a Personalized App to Fight Cancer

We say goodbye to the good weather in Spain and cross the Pyrenees to visit Charleroi, an industrial city south of Brussels. There, we find OncoDNA, a young company striving to change the oncology field using DNA. City: Charleroi, Belgium Founded: 2012 Employees: 11 – 50 Financial data: €7.7M raised in September to expand into the global market Mission: […]

November 4, 2016 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 2 Nov 2016

Antibody Therapies are here to Revolutionize Dermatology

Leo Pharma is offering MorphoSys no less than €111.5M per antibody treatment with applications in dermatology, a very profitable field with big unmet needs. New cancer therapies might also arise from this exciting partnership! MorphoSys is a leader in the development of therapeutic antibodies with top-level partners like Novartis, Roche, Pfizer, Bayer, GSK, Galapagos […]

November 2, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 11 01 at 3.27.32 PM e1478010517232

News and Trends 1 Nov 2016

Novo Nordisk pressured into Dropping Needle-Free Oral Insulin

Needle-free diabetes will have to wait: payers are pressuring pharma to provide lower medication prices, and Novo Nordisk has responded by redirecting its R&D strategy into more innovative research. Despite its position as a world leader in diabetes, Novo Nordisk seems to be hitting a rough patch: the big pharma is reducing its profit and […]

November 1, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 31 Oct 2016

Shooting for the Moon: German Biotech Acquired for a Record €1.3B

Ganymed Pharmaceuticals is the protagonist of Germany’s biggest biotech deal ever; Astellas Pharma has offered up to €1.3B to get hold of Ganymed’s first-in-class cancer antibody technology. Ganymed Pharmaceuticals develops first-in-class antibody therapies for cancer. Its technology seems to be so promising that the Japanese Astellas Pharma has decided to acquire it in what will be the […]

October 31, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 31 Oct 2016

This might be the First 3-in-1 Therapy for Highly Metastatic Cancer

Amcure’s candidate for highly metastatic epithelial cancers is about to start clinical trials. The compound can shut down three oncological pathways simultaneously through a single molecular target. Amcure is a spin-off from the Karlsruhe Institute of Technology in Germany, established in 2012. The company develops treatments for highly metastatic forms of cancer using peptide-based compounds targeting angiogenesis. It […]

October 31, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Clara Rodríguez Fernández

About

Articles by Clara Rodríguez Fernández

British Artificial Intelligence will soon run Clinical Trials

Up, up and away! CureVac’s money pile now Totals €325M

These companies want to use Stem Cells to improve Drug Safety

Green Light for Genfit to Tackle another Liver Disease

Results from 45% of Clinical Trials are kept Secret

The Mind Behind the Artificial Pancreas that Could Change the Lives of Diabetics

Would you Taste this Gene-Edited Dinner?

This Company has developed a Personalized App to Fight Cancer

Antibody Therapies are here to Revolutionize Dermatology

Novo Nordisk pressured into Dropping Needle-Free Oral Insulin

Shooting for the Moon: German Biotech Acquired for a Record €1.3B

This might be the First 3-in-1 Therapy for Highly Metastatic Cancer

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Clara Rodríguez Fernández

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!